Bis-linker Conjugation for Antibody-Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face challenges with off-target toxicity due to unstable linkers, leading to premature release of cytotoxic drugs during circulation, which limits their therapeutic efficacy and increases side effects.
Innovation Solution
The development of bis-linkers that conjugate cytotoxic molecules with cell-binding agents using specific functional groups like amino, hydroxyl, diamino, and thiol, forming stable bonds to enhance circulation stability and reduce off-target toxicity by prolonging half-life and minimizing exposure to non-target cells and tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stable linkers are used in ADCs, then circulation stability is improved, but off-target toxicity is reduced
Solution Approach 1:
The patent divides the linker into two separate linkers (first linker and second linker) that connect the cytotoxic molecule to two different carbohydrate moieties. This segmentation creates a bis-linked structure where the cytotoxic molecule is bridged between two antibody molecules, improving circulation stability while reducing off-target toxicity through controlled drug release only at the target site
Solution Approach 2:
The patent employs a composite structure combining carbohydrate moieties from antibodies with a cytotoxic molecule through bis-linkage. This composite ADC design integrates the stability of glycosidic bonds with the targeting capability of antibodies, achieving both circulation stability and reduced off-target effects
2Ease of operation
If labile linkers are used in ADCs, then drug release upon antigen binding is facilitated, but off-target toxicity increases due to premature release during circulation
Solution Approach 1:
The patent creates different stability characteristics at different locations of the ADC structure. The bis-linker provides stability during circulation, while the glycosidic bonds and enzymatic cleavage sites are positioned to enable controlled drug release specifically at the target site, achieving local quality differentiation between circulation phase and target engagement phase
3Ease of manufacture
If conventional mono-linkage is used, then manufacturing is simpler, but therapeutic index is lower due to off-target toxicity
Solution Approach 1:
The patent employs carbohydrate moieties from antibodies that serve multiple functions: they provide stable attachment points for the cytotoxic molecule, enable site-specific conjugation, and facilitate controlled drug release through enzymatic cleavage. This multi-functionality of the carbohydrate-bis-linker system improves therapeutic index while maintaining manufacturing feasibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bis-linker approach results in ADCs with improved therapeutic index, reduced off-target toxicity, and enhanced anti-tumor activity by maintaining stability during targeted delivery, effectively addressing the limitations of traditional linker technologies.
Implementation Method 1
The development of bis-linkers that conjugate cytotoxic molecules with cell-binding agents using specific functional groups like amino, hydroxyl, diamino, and thiol, forming stable bonds
Implementation Method 2
forming stable bonds to enhance circulation stability and reduce off-target toxicity by prolonging half-life and minimizing exposure to non-target cells and tissues
Data Source
AI summary
A conjugation of a cytotoxic drug to a cell-binding molecule with a bis-linker (dual-linker) as shown in Formula (I). Bis-linkage methods of making a conjugate of a cytotoxic drug/molecule to a cell-binding agent in a specific manner are also described, as well as application of the conjugates for the treatment of a cancer, or an autoimmune disease, or an infectious disease.wherein “” is an optional bond; X, Y, Z1, and Z2 are a functional group; m1 and n are a integer; L1 and L2 are a linker.